Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

40.76 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 40.76
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 40.76
Today's Range 40.76 - 40.76
52wk Range 29.20 - 40.80
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management. 
Via Benzinga
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road. 
Via The Motley Fool

Performance

YTD
+12.13%
+12.13%
1 Month
+17.57%
+17.57%
3 Month
+34.39%
+34.39%
6 Month
+13.79%
+13.79%
1 Year
+5.32%
+5.32%

More News

Read More
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Via Benzinga
This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?
Via The Motley Fool
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
Via The Motley Fool
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
Via Investor's Business Daily
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Via Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
Via Benzinga
Topics Stocks
Exposures US Equities
New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions
From Genentech
Via Business Wire
Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped
Via The Motley Fool
Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study
From Genentech
Via Business Wire
Pfizer And Roche Advance On Their Weight Loss Drug Journeys
Via Benzinga
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Via Benzinga
Roche Highlights Encouraging Data From Newly-Acquired Second Weight Loss Drug Candidate In Early-Stage Study
Via Benzinga
Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity
From Genentech
Via Business Wire
Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)
From Genentech
Via Business Wire
3 Small-Cap Stocks With Explosive 2X Growth Potential
Via InvestorPlace
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
Via Benzinga
FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss
From Genentech
Via Business Wire
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
Via Benzinga
Exposures Product Safety
Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Via Benzinga
Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost
Via InvestorPlace
Exposures Product Safety
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.